Regenxbio (RGNX) Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Regenxbio+%28RGNX%29+Announces+Pivotal+Trial+of+RGX-121+for+the+Treatment+of+MPS+II+Achieves+Primary+Endpoint/22734267.html for the full story.